临床药师参与1例经皮冠状动脉介入术后个体化抗血小板治疗实践  

Individualized Antiplatelet Therapy on One Patient with Stent Thrombosis after Percutaneous Coronary Intervention by Clinical Pharmacist

作　　者：刘俊[1] 朱艳虹[1] 储洁琼[1] 徐文科[1] 汪魏平[1] 栾家杰[1] 

机构地区：[1]皖南医学院弋矶山医院药剂科,安徽芜湖241001

出　　处：《中国药学杂志》2015年第22期2004-2007,共4页Chinese Pharmaceutical Journal

基　　金：皖南医学院中青年科研基金自然科学类资助项目(WK2014F20;WK2014F40)

摘　　要：目的探讨临床药师在经皮冠状动脉介入术后个体化抗血小板治疗中的作用。方法回顾临床药师依据基因检测参与1例经皮冠状动脉介入术后支架内血栓形成的抗血小板治疗的案例。结果临床药师依据基因检测分析经皮冠状动脉介入术后支架内血栓形成的原因,参与抗血小板治疗方案的调整,并对患者提供药学监护和用药教育,保证患者用药安全、有效。结论临床药师依据基因检测参与临床治疗方案的制订和调整,为实施个体化用药提供依据,可作为临床药师药学服务的切入点。OBJECTIVE To evaluate the role of clinical pharmacist in individualized antiplatelet therapy in patients with percutaneous coronary intervention（ PCI）. METHODS To review clinical pharmacist participating antiplatelet therapy based on genotype detection for one patient with stent thrombosis after PCI. RESULTS Clinical pharmacist analyzed the causes of stent thrombosis after PCI by genotype detection,participated the adjustment of antiplatelet therapy and implemented pharmaceutical care and pharmaceutical education for the patient in order to ensure the safety and effectiveness of drug use. CONCLUSION Clinical pharmacist participates making and regulating the therapeutic regimen to provide some evidences for individualized medication,which could be the entry points to pharmaceutical care.

关 键 词：经皮冠状动脉介入术 支架内血栓形成 氯吡格雷抵抗 基因多态性 临床药师 个体化用药 

分 类 号：R969.3[医药卫生—药理学]